Kazia Therapeutics Files Routine 6-K Report
Ticker: KZIA · Form: 6-K · Filed: Jul 10, 2024 · CIK: 1075880
Sentiment: neutral
Topics: sec-filing, foreign-private-issuer, routine-report
Related Tickers: KZA
TL;DR
Kazia Therapeutics (KZA) filed a standard 6-K, no major news.
AI Summary
Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on July 10, 2024. The company, based in Sydney, NSW, Australia, is a foreign private issuer and files annual reports under Form 20-F. The filing does not contain specific financial figures or operational updates but serves as a routine report.
Why It Matters
This filing indicates Kazia Therapeutics is fulfilling its reporting obligations as a foreign private issuer with the SEC, which is standard practice for companies with securities traded in the US.
Risk Assessment
Risk Level: low — This is a routine SEC filing by a foreign private issuer and does not contain new material information or financial disclosures.
Key Players & Entities
- Kazia Therapeutics Limited (company) — Registrant
- Novogen Ltd (company) — Former company name
- July 10, 2024 (date) — Filing date
- Sydney NSW (location) — Company address
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC when they make public certain information available in their home country, such as press releases or financial statements.
When was Kazia Therapeutics Limited previously known as?
Kazia Therapeutics Limited was formerly known as Novogen Ltd, with a date of name change on December 28, 1998.
Where is Kazia Therapeutics Limited headquartered?
Kazia Therapeutics Limited's principal executive office is located at Three International Towers Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.
Does Kazia Therapeutics file annual reports under Form 20-F or 40-F?
Kazia Therapeutics indicates it files annual reports under cover of Form 20-F.
What is the SEC file number for Kazia Therapeutics?
The SEC file number for Kazia Therapeutics is 000-29962.
Filing Stats: 282 words · 1 min read · ~1 pages · Grade level 13 · Accepted 2024-07-10 09:19:25
Filing Documents
- d829960d6k.htm (6-K) — 9KB
- d829960dex991.htm (EX-99.1) — 14KB
- g829960g0710112747712.jpg (GRAPHIC) — 4KB
- 0001193125-24-177072.txt ( ) — 29KB
From the Filing
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrants name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): INFORMATION CONTAINED IN THIS FORM 6-K REPORT On July 10, 2024, Kazia Therapeutics Limited (the Company) issued a press release titled, Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma. A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quote of Dr. John Friend contained in Exhibit 99.1, into the Companys registration statements on Form F-3 (File No. 333-259224 and 333-276091). EXHIBIT LIST Exhibit Description 99.1 Press Release of Kazia Therapeutics Limited dated July 10, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Kazia Therapeutics Limited (Registrant) /s/ John Friend John Friend Chief Executive Officer Date: 10 July 2024